KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Operations: 2019-2025

Historic Cash from Operations for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $702.6 million.

  • Royalty Pharma's Cash from Operations fell 0.14% to $702.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 14.07%. This contributed to the annual value of $2.8 billion for FY2024, which is 7.32% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Cash from Operations is $702.6 million, which was up 93.03% from $364.0 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash from Operations registered a high of $1.0 billion during Q1 2023, and its lowest value of $364.0 million during Q2 2025.
  • For the 3-year period, Royalty Pharma's Cash from Operations averaged around $674.5 million, with its median value being $664.6 million (2024).
  • As far as peak fluctuations go, Royalty Pharma's Cash from Operations skyrocketed by 124.62% in 2023, and later plummeted by 44.70% in 2025.
  • Over the past 5 years, Royalty Pharma's Cash from Operations (Quarterly) stood at $490.0 million in 2021, then increased by 16.32% to $569.9 million in 2022, then skyrocketed by 35.57% to $772.6 million in 2023, then decreased by 3.90% to $742.5 million in 2024, then decreased by 0.14% to $702.6 million in 2025.
  • Its Cash from Operations was $702.6 million in Q3 2025, compared to $364.0 million in Q2 2025 and $596.1 million in Q1 2025.